Home › Trials › NCT06806813

Registry for understanding cardiovascular issues in Fabry Disease

Italian Anderson Fabry Disease Cardiovascular Registry

Observational IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06806813

This study is trying to learn more about heart problems in people with Fabry Disease to help improve their care and outcomes.

Quick facts

Study typeObservational
Enrollment800 (estimated)
Ages2 Years and up
SexAll
SponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna Academic / other
Locations54 sites (Chieti, Abruzzo/Chieti and 53 other locations)
Trial IDNCT06806813 on ClinicalTrials.gov

What this trial studies

The RICMAF Study is an observational, multicenter initiative in Italy aimed at improving the understanding of Anderson-Fabry Disease (AFD), particularly its cardiac manifestations. By collecting data from a nationwide patient registry, the study seeks to analyze the clinical profile, prevalence, and incidence of AFD, as well as identify early markers of cardiac involvement and predictors of cardiovascular complications. The study also aims to explore the relationship between genetic mutations and clinical presentation to enhance personalized care for patients. This comprehensive approach is designed to improve patient outcomes through better understanding and management of the disease.

Who should consider this trial

Good fit: Ideal candidates for this study are patients diagnosed with Anderson Fabry Disease who are aged 2 years or older.

Not a fit: Patients who do not have a diagnosis of Anderson Fabry Disease will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved diagnosis and management of Fabry Disease, particularly in preventing cardiovascular complications.

How similar studies have performed: Other studies focusing on the clinical aspects of rare diseases like Fabry Disease have shown promise, indicating that this approach may yield valuable insights.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Patients diagnosed with Anderson Fabry disease
* Age ≥ 2 years at diagnosis
* Obtaining informed consent from the patient and parent or legal guardian.

Exclusion Criteria:

\- None

Where this trial is running

Chieti, Abruzzo/Chieti and 53 other locations

+4 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Fabry DiseaseFabry
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.